What is GISSI
In the twenty years since their beginning, the GISSI studies have obtained wide recognition in the international world of cardiology and are considered a methodological landmark.
The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI), born from the collaboration between the Mario Negri Institute and the Associazione Nazionale dei Medici Cardiologi Ospedalieri (ANMCO), is considered today one of the most characterized research team in the cardiovascular field. The GISSI has produced a series of large-scale clinical trials (GISSI 1, GISSI 2, GISSI 3, GISSI Prevention), that have involved more than 60.000 patients with myocardial infarction (AMI).
GISSI 1 has demonstrated that thrombolytic therapy is able to reduce mortality after myocardial infarction.
The GISSI 2 and GISSI 3 trials have produced important information on the other therapies aside the trombolytic therapy.
GISSI 3 demonstrated that the early use of ACE-inhibitors can furtherly improve the survival after AMI.
The GISSI Prevenzione assessed in patients with a previous AMI the effectiveness of a therapy with n-3 PUFA, vitamin E and a statin showing a reduction of mortality of 20% in patients treated with n-3 PUFA. In the last 20 years the in-hospital mortality due to AMI has been reduced for approximately the 30%.
Besides their results on the efficacy of the experimental treatments, these studies have contributed knowledge on different aspects: